Antidepressants: pharmacological profile and clinical consequences

REFERENCES

• Quetsch RM, Achor RWP, Litin EM, Faucett RL (1959) Depressive reactions in hypertensive patients: a comparison of those treated with rauwolfia and those receiving no specific anti-hypertensive treatment. Circulation 19: 366–75.
   PubMedGoogle Scholar
• Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122: 509–22.
   PubMed Web of Science ®Google Scholar
• Bunney Jr WE, Davis JM (1965) Norepinephrine in depressive reactions: a review. Arch Gen Psychiatry 13: 483–94.
   Google Scholar
• Coppen A (1967) The biochemistry of affective disorders. Br J Psychiatry 113: 1237–64.
   PubMed Web of Science ®Google Scholar
• Shelton RC (2000) Intracellular mechanisms of antidepressant drug action. Harvard Rev Psychiatry 8: 161–74.
   PubMed Web of Science ®Google Scholar
• Delgano PL, Price LH, Miller HL et al (1994) Serotonin and the neurobiology of depression: effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 51: 865–74.
   Google Scholar
• Miller HL, Delgano PL, Salomon RM et al (1996) Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 53: 117–28.
   Google Scholar
• Berman RM, Narasimhan M, Miller HL et al (1999) Transient depressive relapse induced by catecholamine depletion: potential phenotypic vulnerability marker? Arch Gen Psychiatry 56: 395–403.
   Google Scholar
• Stahl SM (1997) The selective serotonin reuptake inhibitors. In: Stahl SM, Psychopharmacology of Antidepressants. Martin Dunitz, London. 39–60.
   Google Scholar
• Anand A, Charney DS (2000) Norepinephrine dysfunction in depression. J Clin Psychiatry 61 (suppl 10)</b>: 16–24.
   Google Scholar
• Jimerson, DC (1987) Role of dopamine mechanisms in the affective disorders. In Psychopharmacology: The third generation of progress (ed. HY Meltzer) Raven Press, New York. p. 505–511.
   Google Scholar
• Preskorn SH (1996) Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. Professional Communications, Caddo, OH.
   Google Scholar
• Racagni G, Brunello N (1999) Physiology to functionality: the brain and neurotransmitter activity. Int Clin Psychopharmacol 14 (suppl 1)</b>: S3–7.
   Google Scholar
• Fraser A (2000) Norepinephrine involvement in antidepressant action. J Clin Psychiatry 61 (suppl 10)</b>: 25–30.
   Google Scholar
• Leonard BE (1997) Drug treatment of depression. In: Funda- mentals of Psychopharmacology. Wiley, Chichester. 107–42.
   Google Scholar
• Charney DS (1998) Monoamine dysfunction and the patho- physiology and treatment of depression. J Clin Psychiatry 59 (suppl 14): 11–14.
   Google Scholar
• Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM (1997) Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 56: 131–7.
   PubMed Web of Science ®Google Scholar
• Duman RS, Heninger GR, Nestler EJ (1997) A molecular and cellular theory of depression. Arch Gen Psychiatry 54: 597–606.
   PubMed Web of Science ®Google Scholar
• Duman RS, Malberg J, Thome J (1999) Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 46: 1181–91.
   PubMed Web of Science ®Google Scholar
• Nibuya M, Morinobu S, Duman RS (1995) Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15: 7539–47.
   PubMed Web of Science ®Google Scholar
• Stokes PE (1993) Fluoxetine: a five-year review. Clin Ther 15: 216–43.
   Google Scholar
• Judge R, Plewes JM, Kumar V et al (2000) Changes in energy during treatment of depression: an analysis of fluoxetine double-blind, placebo controlled trials. J Clin Pharmacol 20: 666–72.
   Google Scholar
• DeVane CL (1995). Comparative safety and tolerability of selective serotonin reuptake inhibitors. Human Psychopharma- col 10: S185–93.
   Google Scholar
• Stahl SM (1998) Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. J Clin Psychiatry 59 (suppl 18)</b>: 23–9.
   Google Scholar
• Stahl SM (1996) Antidepressants and mood stabilizers. In: Stahl S, Essential Psychopharmacology: Neuroscientific basis and clinical applications. Cambridge University Press, Cambridge. 131–66.
   Google Scholar
• Masand PS, Gupta S (1999) Selective serotonin reuptake inhibitors: an update. Harvard Rev Psychiatry 7: 69–84.
   PubMed Web of Science ®Google Scholar
• Simon GE, Von Korff M, Heiligenstein JH et al (1999) Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 275: 1897–1902.
   Google Scholar
• Wong BT, Bymaster FP, Horn BS, Malloy BB (1975) A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3(P-trifluoromethylphenoxy)-N-methyl-3-phenylpro- pylamine. J Pharmacol Exp Ther 193: 804–11.
   PubMed Web of Science ®Google Scholar
• Stokes PE, Holtz A (1997) Fluoxetine tenth anniversary update: the progress continues. Clin Ther 19: 1–86.
   Google Scholar
• Hughes ZA, Stanford SC (1996) Increased noradrenaline efflux induced by local infusion of fluoxetine in the rat frontal cortex. Eur J Pharmacol 317: 83–90.
   PubMed Web of Science ®Google Scholar
• Perry KW, Fuller RW (1997) Fluoxetine increases norepi- nephrine release in rat hypothalamus as measured by tissue levels of MHPG-SO4 and microdialysis in conscious rats. J Neural Transm 104: 953–66.
   PubMed Web of Science ®Google Scholar
• Simon B, Appel JB (1997) Dopaminergic and serotonergic properties of fluoxetine. Prog Neuropsychopharmacol Biol Psych 21: 169–81.
   Google Scholar
• Tollefson GD, Holman SL (1993) Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo- controlled trial of fluoxetine in geriatric major depression. Int Clin Psychopharmacol 8: 253–9.
   Google Scholar
• Edwards JG, Anderson I (1999) Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57: 507–33.
   PubMed Web of Science ®Google Scholar
• Noble S, Benfield P (1997) Citalopram: a review of its pharmacology, clinical efficacy, and tolerability in the treatment of depression. CNS Drugs 8: 410–331.
   Web of Science ®Google Scholar
• Danish University Antidepressant Group (DUAG) (1986) Citalopram: clinical effect profile in comparison with clomi- pramine. A controlled multicenter study. Psychopharmacology 90: 131–8.
   PubMed Web of Science ®Google Scholar
• Finley PR (1994) Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann Pharmacother 28: 1359–69.
   PubMed Web of Science ®Google Scholar
• Danish University Antidepressant Group (DUAG) (1990) Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance but weaker antidepressant effect than clomi- pramine in a controlled multicenter study. J Affect Disord 18: 289–99.
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Haddad P (2000) Compliance with anti- depressant therapy and antidepressant discontinuation symp- toms. Acta Psychiatr Scand 101 (suppl 403): 50–6.
   Google Scholar
• Goodnick PJ, Goldstein BJ (1998) Selective serotonin reuptake inhibitors in affective disorders. I. Basic pharmacology. J Psychopharmacol 12 (suppl B)</b>: S5–20.
   Google Scholar
• Hyttel J (1993) Comparative pharmacology of selective serotonin reuptake inhibitors (SSRIs). Nord J Psychiatry 47 (suppl 30): 5–20.
   Google Scholar
• Grimsley SR, Jann MW (1992) Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharmacol 11: 930–57.
   PubMedGoogle Scholar
• Stahl S (2000). Newer antidepressants and mood stabilizers. In: Stahl S, Essential Psychopharmacology: Neuroscientific basis and clinical applications. Cambridge University Press, Cambridge, 245–95.
   Google Scholar
• Gunick JF, Nemeroff CB (2000) Problems with currently available antidepressants. J Clin Psychiatry 61 (suppl 10)</b>: 5–15.
   Google Scholar
• Freemantle N, Anderson IM, Young P (2000) Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Br J Psychiatry 177: 292–302.
   Google Scholar
• Tylee A, Gastpar M, LeÂpine J-P, Mendelwicz J (1999) Identification of patient types in the community and their treatment needs: findings from the DEPRES II (Depression Research in European Society II) Survey. Int Clin Psychophar- macol 14: 153–65.
   Google Scholar
• DeVane CL (1998) Differential pharmacology of newer antidepressants. J Clin Psychiatry 59 (suppl 20): 85–93.
   Google Scholar
• Schatzberg, AF (2000). Clinical efficacy of reboxetine in major depression. J Clin Psychiatry 61 (suppl 10)</b>: 31–38.
   Google Scholar
• Tylee A, Gastpar M, Lepine LP, Mendlewicz J (1999) DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. Int Clin Psychopharmacol 14: 139–51.
   Google Scholar
• Clayton PJ (1998) Depression subtyping: treatment implica- tions. J Clin Psychiatry 59 (suppl 16): 5–12.
   Google Scholar
• Preskorn SH (2000) The adverse event profiles of the selective serotonin reuptake inhibitors: relationship to in vitro pharma- cology. J Psychiatr Practice 6: 153–7.
   Google Scholar
• Preskorn SH (2000) The relative adverse event profile of non- SSRI antidepressants: relationship to in vitro pharmacology. J Psychiatr Practice 6: 218–23.
   Google Scholar